| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 125.81 KB | Adobe PDF |
Advisor(s)
Abstract(s)
This study aimed to assess the cardio-renal effects of rhEPO therapy on an animal
model of moderate chronic renal failure (CRF). Four groups (n =7) of male rat were
evaluated during a 12-week follow up period: control; rhEPO: 50 IU/Kg/wk; CRF:
two-stage 3/, nephrectomy; CRF+ rhEPO (start after the 3'd wk of surgery). Renal
function, haematology and serum inflammation and redox status were assessed. rhEPO
treatment was able to partially attenuate renal function markers, totally correct
anaemia, also showing a proliferative and antioxidant action, due to increased serum
TGF-13I and decreased 3-NT. In conclusion, rhEPO therapy might be recommended in
moderate CRF stages in order to efficiently correct not only the underlying anaemia
but also the deleterious cardio-renal effects, due to a proliferative and antioxidant renoprotective action.
Description
Keywords
Moderate chronic renal failure rhEPO therapy Cardio-renal effects
Pedagogical Context
Citation
CONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS, 9th. Edinburgh, Scotland, United Kingdom, 12-15 July, 2009. In Proceedings of the European Association for Clinical Pharmacology and Therapeutics, p. 177 - 180
Publisher
Medimond S.r.l. - Monduzzi Editore International Proceedings Division